2024Title: MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)Protocol Number: ITL-2001-CL-301Sponsor: Intellia TherapeuticsRole: Ophthalmic assessment site
2023 - OngoingTitle: ASPIRE: A Randomized, Double-Blind Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal AdenocarcinomaProtocol Number: CL-SBP-101-04Sponsor: Panbela TherapeuticsRole: Ophthalmic assessment site
2019 Title: A Clinical effectiveness, multicenter, randomised, double-controlled study of the efficacy and safety of INS-5010 in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degenerationProtocol Number: ONS-5010-002Sponsor: GreenLight ClinicalRole: Principal Investigator 2018-2019 Title: Identifying microRNA and Vascular Endothelial Growth Factor (VEGF) changes in the. Blood of Age-related Macular Degeneration (AMD) patientsGrants: Canberra Health Services Private Practice Fund and Bayer AustraliaRole: Principal Investigator